TD Private Client Wealth LLC Buys 1,607 Shares of Becton, Dickinson and Company (NYSE:BDX)

TD Private Client Wealth LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 44.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,210 shares of the medical instruments supplier's stock after acquiring an additional 1,607 shares during the quarter. TD Private Client Wealth LLC's holdings in Becton, Dickinson and Company were worth $1,193,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its stake in Becton, Dickinson and Company by 10.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,020,625 shares of the medical instruments supplier's stock worth $233,784,000 after purchasing an additional 93,926 shares in the last quarter. Penserra Capital Management LLC increased its stake in Becton, Dickinson and Company by 394.0% in the 1st quarter. Penserra Capital Management LLC now owns 3,735 shares of the medical instruments supplier's stock worth $855,000 after purchasing an additional 2,979 shares in the last quarter. Hendley & Co. Inc. purchased a new position in Becton, Dickinson and Company in the 1st quarter worth about $204,000. McGlone Suttner Wealth Management Inc. purchased a new position in Becton, Dickinson and Company in the 1st quarter worth about $305,000. Finally, Concurrent Investment Advisors LLC grew its stake in Becton, Dickinson and Company by 6.3% during the 1st quarter. Concurrent Investment Advisors LLC now owns 11,423 shares of the medical instruments supplier's stock valued at $2,617,000 after acquiring an additional 673 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research analyst reports. Raymond James Financial cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Morgan Stanley lowered their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research note on Friday, May 2nd. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target for the company. in a research note on Thursday, May 1st. Finally, William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Stock Performance

BDX traded up $1.86 on Thursday, hitting $177.36. The company had a trading volume of 3,014,067 shares, compared to its average volume of 2,075,925. The company's fifty day moving average price is $172.03 and its 200 day moving average price is $206.75. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The stock has a market cap of $50.83 billion, a price-to-earnings ratio of 33.85, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the previous year, the company earned $3.17 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.

Insider Activity

In other news, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.